A phase 2a trial of NMD Pharma’s rare disease prospect ignaseclant has missed its primary endpoint. | A phase 2a trial of NMD ...

The FDA has requested that Amgen voluntarily withdraw avacopan (Tavneos), a treatment for anti-neutrophil cytoplasmic ...

Study suggests that persistently activated ATF6α is a tumor driver, a potential stratification marker for immunotherapy response, and a therapeutic target for HCC.

Lindsey Vonn posted a video of her doing leg workouts not even a week after she tore her ACL while preparing for the Olympics ...

A research team from POSTECH and ImmunoBiome in Korea, led by Professor Sin-Hyeog Im, has uncovered a new mechanism showing ...

Leveraging human organoid-based mechanistic investigation, researchers reveal how an immunosuppressive drug, antithymocyte ...

Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steven Perrin, Ph.D., President and Chief Scientific Officer will participate in a fireside chat at the upcoming Guggenheim ...

Researchers at University of Tsukuba have discovered that an immunosuppressive drug affects microglia, the resident immune ...

Healthy adults trained to upregulate reward circuitry using neurofeedback showed stronger immune responses to HBV vaccination ...

DipCoin today announced the official launch of its Season 1: Horizon Points & Referral System, marking the activation of ...

A key molecular mechanism drives the growth of liver cell cancer while simultaneously suppressing the body's immune response ...